BLRX
BioLineRx Ltd.
$2.27
$0.00(0.00%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$10.01M
Volume
15.62K
52W Range
$2.15 - $7.77
Target Price
$20.33
Company Overview
| Mkt Cap | $10.01M | Price | $2.27 |
| Volume | 15.62K | Change | +0.00% |
| P/E Ratio | -1.1 | Open | $2.29 |
| Revenue | $22.9M | Prev Close | $2.27 |
| Net Income | $-9.2M | 52W Range | $2.15 - $7.77 |
| Div Yield | N/A | Target | $20.33 |
| Overall | 18 | Value | -- |
| Quality | -- | Technical | 18 |
No chart data available
About BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Sector: Healthcare
Industry: Biotechnology
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BLRX | $2.27 | 0% | 15.62K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |